ASH 2023 | Stem cell transplantation conditioning in AML: making the decision between MAC and RIC
Charles Craddock
• 10 Dec 2023
Charles Craddock, CBE, FRCP(UK), FRCPath, DPhil, FMedSci, University of Birmingham, discusses the use of myeloablative conditioning (MAC) versus reduced-intensity conditioning (RIC) regimens for stem cell transplantation (SCT) in patients with acute myeloid leukemia (AML). Dr Craddock recommends MAC for young and fit patients, whereas he suggests that RIC is a more suitable option for older patients due to the toxicity associated with MAC. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: BMS, Abbvie
Research Funding: BMS
